Why didn't the company issue a press release on FA results?
Take a look at the news section of the MDA website. Encouraging data on the FA drug from a news story published on May 17. No SAEs, no dropouts, messenger RNA up in 9 of 10 patients, and possible increase in frataxin protein in 3 of 10 patients. Why didn't the company issue a release on this? Maybe they are finalizing a deal for the compound and the acquirer controls the info?
Getting more bullish with this premature but positive information - also with the increase short positions and the prospects of news of acquisition or new partnership or 1068 = this can quickly jump a $1 - $2 - exciting.
Thanks very much. RGEN was probably under some pressure from MDA to release some preliminary data since MDA helped fund the study.
The study was not finished at the time of the presentation. Group 4 had not received its second dose.
Anyway, the study was not a flop. It was encouraging. Difficult to interpret because phase 1 studies evaluate safety and extremely low doses of the drug were administered. Even with extremely low doses there was an indication that flataxin levels increased in some patients.
Thanks again. I think the full report, when released, will sound pretty encouraging.